Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type

Lattice corneal dystrophy gelsolin type was first described in 1969 by Jouko Meretoja, a Finnish ophthalmologist. It is caused by an autosomal dominant mutation in gelsolin gene resulting in unstable protein fragments and amyloid deposition in various organs. The age of onset is usually after the th...

Full description

Saved in:
Bibliographic Details
Main Authors: I. Casal, S. Monteiro, C. Abreu, M. Neves, L. Oliveira, M. Beirão
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2017/2843417
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850218314147561472
author I. Casal
S. Monteiro
C. Abreu
M. Neves
L. Oliveira
M. Beirão
author_facet I. Casal
S. Monteiro
C. Abreu
M. Neves
L. Oliveira
M. Beirão
author_sort I. Casal
collection DOAJ
description Lattice corneal dystrophy gelsolin type was first described in 1969 by Jouko Meretoja, a Finnish ophthalmologist. It is caused by an autosomal dominant mutation in gelsolin gene resulting in unstable protein fragments and amyloid deposition in various organs. The age of onset is usually after the third decade of life and typical diagnostic triad includes progressive bilateral facial paralysis, loose skin, and lattice corneal dystrophy. We report a case of a 53-year-old female patient referred to our Department of Ophthalmology by severe dry eye and incomplete eyelid closure. She had severe bilateral facial paresis, significant orbicularis, and perioral sagging as well as hypoesthesia of extremities and was diagnosed with Meretoja’s syndrome at the age of 50, confirmed by the presence of gelsolin mutation. At our observation she had bilateral diminished tear film break-up time and Schirmer test, diffuse keratitis, corneal opacification, and neovascularization in the left eye. She was treated with preservative-free lubricants and topical cyclosporine, associated with nocturnal complete occlusion of both eyes, and underwent placement of lacrimal punctal plugs. Ocular symptoms are the first to appear and our role as ophthalmologists is essential for the diagnosis, treatment, and monitoring of ocular alterations in these patients.
format Article
id doaj-art-3aa98cb1cf2043c7afa4faf4287e9863
institution OA Journals
issn 1687-9627
1687-9635
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-3aa98cb1cf2043c7afa4faf4287e98632025-08-20T02:07:47ZengWileyCase Reports in Medicine1687-96271687-96352017-01-01201710.1155/2017/28434172843417Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin TypeI. Casal0S. Monteiro1C. Abreu2M. Neves3L. Oliveira4M. Beirão5Centro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalCentro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalCentro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalCentro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalCentro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalCentro Hospitalar do Porto, Hospital de Santo António, Porto, PortugalLattice corneal dystrophy gelsolin type was first described in 1969 by Jouko Meretoja, a Finnish ophthalmologist. It is caused by an autosomal dominant mutation in gelsolin gene resulting in unstable protein fragments and amyloid deposition in various organs. The age of onset is usually after the third decade of life and typical diagnostic triad includes progressive bilateral facial paralysis, loose skin, and lattice corneal dystrophy. We report a case of a 53-year-old female patient referred to our Department of Ophthalmology by severe dry eye and incomplete eyelid closure. She had severe bilateral facial paresis, significant orbicularis, and perioral sagging as well as hypoesthesia of extremities and was diagnosed with Meretoja’s syndrome at the age of 50, confirmed by the presence of gelsolin mutation. At our observation she had bilateral diminished tear film break-up time and Schirmer test, diffuse keratitis, corneal opacification, and neovascularization in the left eye. She was treated with preservative-free lubricants and topical cyclosporine, associated with nocturnal complete occlusion of both eyes, and underwent placement of lacrimal punctal plugs. Ocular symptoms are the first to appear and our role as ophthalmologists is essential for the diagnosis, treatment, and monitoring of ocular alterations in these patients.http://dx.doi.org/10.1155/2017/2843417
spellingShingle I. Casal
S. Monteiro
C. Abreu
M. Neves
L. Oliveira
M. Beirão
Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
Case Reports in Medicine
title Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
title_full Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
title_fullStr Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
title_full_unstemmed Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
title_short Meretoja’s Syndrome: Lattice Corneal Dystrophy, Gelsolin Type
title_sort meretoja s syndrome lattice corneal dystrophy gelsolin type
url http://dx.doi.org/10.1155/2017/2843417
work_keys_str_mv AT icasal meretojassyndromelatticecornealdystrophygelsolintype
AT smonteiro meretojassyndromelatticecornealdystrophygelsolintype
AT cabreu meretojassyndromelatticecornealdystrophygelsolintype
AT mneves meretojassyndromelatticecornealdystrophygelsolintype
AT loliveira meretojassyndromelatticecornealdystrophygelsolintype
AT mbeirao meretojassyndromelatticecornealdystrophygelsolintype